Showing results (201-210 of 219) with videos related to
Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)Alberto Puccini, Kelsey Poorman, Mohamed E Salem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract CancersRachna T Shroff, Gentry King, Sarah Colby, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.ESMO Open|June 25, 2020
Molecular profile of BRCA-mutated biliary tract cancersGilbert Spizzo, Alberto Puccini, Joanne Xiu, et al.NPJ Precision Oncology|October 28, 2021
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patientsAlberto Puccini, Andreas Seeber, Joanne Xiu, et al.Molecular Cancer Therapeutics|September 13, 2023
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung CancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.American Journal of Clinical Oncology|January 28, 2020
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical TrialRoss A Abrams, Kathryn A Winter, Howard Safran, et al.The Lancet. Gastroenterology & Hepatology|August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.Journal of the National Cancer Institute|March 20, 2025
Utilizing Patient Input in Rectal Cancer Trial DesignJanet Alvarez, Wini Zambare, Manju George, et al.Pageof 22